Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: A systematic review and meta-analysis

European Journal of Clinical Pharmacology

Volumn 69, Issue 12, 2013, Pages 2001-2009

  Yan, Y L ^a   Qiu, B ^a   Hu, L J ^a   Jing, X D ^a   Liu, Y J ^a   Deng, S B ^a   Du, J L ^a   She, Q ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Coronary heart disease; Intensive statin therapy; Meta analysis; Systematic review

Indexed keywords

ATORVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CREATINE KINASE BLOOD LEVEL; DATA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; GERIATRIC DISORDER; HEART ARREST; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; META ANALYSIS; MYOPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

CORONARY DISEASE; HEART ARREST; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; STROKE; TREATMENT OUTCOME;

EID: 84892374541     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1570-0     Document Type: Review

References (21)

1. Hoeg JM, Brewer HJ (1987) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia [J]. JAMA 258(24):3532-6
2. Mantell G (1989) Lipid lowering drugs in atherosclerosis-the HMG-CoA reductase inhibitors [J]. Clin Exp Hypertens A 11(5-6):927-41
3. Hsu I, Spinler SA, Johnson NE (1995) Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia[J]. Ann Pharmacother 29(7-8):743-59
4. Byington RP, Jukema JW, Salonen JT et al (1995) Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program [J]. Circulation 92(9):2419-25
5. Dupuis J, Tardif JC, Cernacek P et al (1999) Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial [J]. Circulation 99(25):3227-33
6. Alber HF, Frick M, Süssenbacher A et al (2007) Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease[J]. Wien Med Wochenschr 157(3-4):73-8
7. Oka H, Ikeda S, Koga S et al (2008) Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases[J]. Hear Vessel 23(4):249-56
8. Josan K, Majumdar SR, McAlister FA (2008) The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials [J]. CMAJ 178(5):576-84
9. Baigent C, Blackwell L, Emberson J et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials[J]. Lancet 376(9753):1670-81
10. Olsson AG, Schwartz GG, Szarek M, et al (2007) Effects of high-dose atorvastatin in patients>or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study) [J]. Am J Cardiol 99(5):632-5
11. Deedwania P, Stone PH, Bairey Merz CN et al (2007) Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE) [J]. Circulation 115(6):700-7
12. Wenger NK, Lewis SJ, Herrington DM et al (2007) Outcomes of using high-or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease [J]. Ann Intern Med 147(1):1-9
13. Koren MJ, Feldman T, Mendes RA (2009) Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years [J]. Clin Cardiol 32(5):256-63
14. Tikkanen MJ, Holme I, Cater NB et al (2009) Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40mg) in Patients Aged <65 Versus> 65 Years With Coronary Heart Disease (from the Incremental Decrease through Aggressive Lipid Lowering [IDEAL] Study) [J]. Am J Cardiol 103(5):577-582
15. Baigent C, Keech A, Kearney PM et al (2005) Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomized trials of statins [J]. Lancet 366(9493):1267-78
16. Grundy SM, Cleeman JI, Merz CN et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines[J]. Circulation 110(2):227-39
17. de Lemos JA, Blazing MA, Wiviott SD et al (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial [J]. JAMA 292(11):1307-16
18. Rouleau J (2005) Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE ITTIMI 22) trial [J]. Am J Med 118(12A):28-35
19. LaRosa JC, Grundy SM, Waters DD et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease [J]. N Engl J Med 352(14):1425-35
20. Pedersen TR, Faergeman O, Kastelein JJ et al (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [J]. JAMA 294(19):2437-45
21. Mills EJ, O'Regan C, Eyawo O et al (2011) Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients [J]. Eur Hear J 32(11):1409-1415